These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35554915)

  • 41. Cytopathic Effect (CPE )-Based Drug Screening Assay for SARS-CoV-2.
    Ng YL; Mok CK; Chu JJH
    Methods Mol Biol; 2022; 2452():379-391. PubMed ID: 35554918
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Progress in understanding COVID-19: insights from the omics approach.
    Lin B; Liu J; Liu Y; Qin X
    Crit Rev Clin Lab Sci; 2021 Jun; 58(4):242-252. PubMed ID: 33375876
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Repositioning of Drugs to Counter COVID-19 Pandemic - An Insight.
    Akilesh SM; J R; Palanisamy D; Wadhwani A
    Curr Pharm Biotechnol; 2021; 22(2):192-199. PubMed ID: 32867651
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Therapeutic Journey of Potential Drugs Against COVID-19.
    Ali F; Hussain S; Zhu YZ
    Mini Rev Med Chem; 2022; 22(14):1876-1894. PubMed ID: 33845740
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Potential inhibitors of SARS-CoV-2: recent advances.
    Jamalipour Soufi G; Iravani S
    J Drug Target; 2021 Apr; 29(4):349-364. PubMed ID: 33210953
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dose Selection in a Pandemic: A Framework Informed by the FDA Animal Rule.
    Wu K; Bergman KL
    Clin Transl Sci; 2021 Jan; 14(1):5-7. PubMed ID: 33201590
    [No Abstract]   [Full Text] [Related]  

  • 47. Antiviral properties of copper and its alloys to inactivate covid-19 virus: a review.
    Govind V; Bharadwaj S; Sai Ganesh MR; Vishnu J; Shankar KV; Shankar B; Rajesh R
    Biometals; 2021 Dec; 34(6):1217-1235. PubMed ID: 34398357
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Network-Driven Drug Discovery.
    Wray J; Whitmore A
    Methods Mol Biol; 2022; 2390():177-190. PubMed ID: 34731469
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A public-private partnership for the express development of antiviral leads: a perspective view.
    Mayburd A
    Expert Opin Drug Discov; 2021 Jan; 16(1):23-38. PubMed ID: 32877233
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phylodynamic analysis in the understanding of the current COVID-19 pandemic and its utility in vaccine and antiviral design and assessment.
    Cardona-Ospina JA; Rojas-Gallardo DM; Garzón-Castaño SC; Jiménez-Posada EV; Rodríguez-Morales AJ
    Hum Vaccin Immunother; 2021 Aug; 17(8):2437-2444. PubMed ID: 33606594
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Prevention and treatment of COVID-19 based on post-genomic pharmacological analysis: Systematic computer analysis of 290,000 scientific articles on COVID-19].
    Torshin IY; Gromova OA; Chuchalin AG
    Ter Arkh; 2024 Apr; 96(3):205-211. PubMed ID: 38713033
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV): Designing Master Protocols for Evaluation of Candidate COVID-19 Therapeutics.
    LaVange L; Adam SJ; Currier JS; Higgs ES; Reineck LA; Hughes EA; Read SW;
    Ann Intern Med; 2021 Sep; 174(9):1293-1300. PubMed ID: 34181444
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Meeting report: 34th international conference on antiviral research.
    Brancale A; Carter K; Delang L; Deval J; Durantel D; Gentry BG; Jordan R; Julander JG; Lo MK; Pérez-Pérez MJ; Schang LM; Seley-Radtke KL; Shi PY; Vasudevan SG; Whitley RJ; Spengler JR
    Antivir Chem Chemother; 2022; 30():20402066221130853. PubMed ID: 36305015
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combating Viral Diseases in the Era of Systems Medicine.
    Bai JPF; Guo EY
    Methods Mol Biol; 2022; 2486():87-104. PubMed ID: 35437720
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The pandemic and resilience for the future: AccBio 2021.
    McGovern ĀT; Salisbury CM; Nyberg GB
    Biotechnol Prog; 2022 Jan; 38(1):e3207. PubMed ID: 34463436
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Looking at COVID-19 from a Systems Biology Perspective.
    Turilli ES; Lualdi M; Fasano M
    Biomolecules; 2022 Jan; 12(2):. PubMed ID: 35204689
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Transforming drug development with synthetic biology and AI.
    Hill A; True JM; Jones CH
    Trends Biotechnol; 2024 Sep; 42(9):1072-1075. PubMed ID: 38383215
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacology of COVID-19.
    Sureda A; Habtemariam S; Nabavi SM
    Chem Biol Interact; 2022 Aug; 362():110005. PubMed ID: 35662545
    [No Abstract]   [Full Text] [Related]  

  • 59. Meeting report: 36th International Conference on Antiviral Research in Lyon, France - March 13-17, 2023.
    Spengler JR; Carter K; Delang L; Durantel D; Gowen BB; Herrero LJ; Hurst B; Janeba Z; Jordan R; Luo D; Meier C; Moffat J; Rocha-Pereira J; Seley-Radtke KL; Welch SR; Schang LM
    Antiviral Res; 2023 Sep; 217():105678. PubMed ID: 37494979
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Strategies to Promote Equity in COVID-19 Antiviral Treatment.
    Fiscella K; Sanders M; Yaeger J
    JAMA Health Forum; 2022 Mar; 3(3):e220050. PubMed ID: 36218879
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.